Dr James Watson
Contact information
Podcast interview
Data driven definitions of severe malaria

James studies severe malaria in African children, focusing on improving diagnostic accuracy. By analysing clinical data, he aims to distinguish malaria-related severe illness from other infections and estimate true mortality more reliably. His work supports faster diagnosis and treatment, ultimately reducing preventable child deaths in low-resource settings.
Research groups
James Watson
IDDO Associate Director
Clinical Therapeutics
I am a statistician interested in improving the treatment of infectious diseases of global health importance. My main work focuses on severe malaria, notably improving the definition of severe malaria in areas of high malaria transmission. We have estimated that a third of children diagnosed with severe malaria in high transmission settings in fact have another cause of severe illness.
I also work on other infectious diseases: I am an investigator and study statistician for PLATCOV, a platform trial characterising in vivo antiviral effects of repurposed or novel drugs for COVID-19; I am an investigator on the CHARM project which aims to develop a new methodology for the assessment of new antiparasitic drugs for the treatment of Chagas disease.
Causal pathways in severe malaria
Recent publications
Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings
Journal article
White NJ. and Watson JA., (2026), The Lancet Infectious Diseases, 26, e240 - e247
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)
Journal article
Yacoub S. et al, (2026), The Lancet Infectious Diseases, 26, e231 - e244
Accurate Measurement of Viral Clearance in Early-Phase Antiviral Studies in Coronavirus Disease 2019
Journal article
Wongnak P. et al, (2026), The Journal of Infectious Diseases, 233, e582 - e584
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Journal article
Schilling WHK. et al, (2026), The Lancet Infectious Diseases, 26, 139 - 147